NSE: JENBURPH · BSE: 524731
JENBURKT PHARMACEUTICAL L
Operates in the pharmaceuticals sector, reporting FY26 revenue of ₹168.74 crore, up 11.2% year-on-year, with net profit of ₹34.74 crore. The cost structure is unusual for a pharmaceutical — raw materials account for only 5.3% of revenue while employee costs at 29.6% are the largest single line item, pointing to a sales-and-marketing-led model rather than bulk drug manufacturing. Other operating expenses take another 25.4% of revenue, with depreciation at just 1.8% reflecting a relatively asset-light base. The balance sheet is debt-free with zero borrowings and reserves of ₹17,847 lacs as of H1 FY26. Capital expenditure of ₹13.72 crore in FY26 and capital work in progress of ₹5,221 lacs at H1 FY26 indicate ongoing capacity expansion. An exceptional charge of ₹395.11 lakhs was recorded in FY26 due to revised Indian Labour Codes raising gratuity and leave liabilities. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Pharmaceuticals. Asset-light, debt-free pharma with high employee intensity
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 124 | 137 | 142 | 152 | 169 |
| EBITDA (ex other income) | 27 | 30 | 33 | 40 | 40 |
| margin % | 22.0 | 22.2 | 23.3 | 26.6 | 23.6 |
| Owners' profit | 22 | 25 | 26 | 32 | 35 |
| EPS, as reported (₹) | 48.58 | 53.90 | 58.86 | 72.65 | 78.71 |
| ROE % · ROCE % | 19.0 · 24.9 | 20.1 · 26.4 | 17.9 · 23.8 | 18.7 · 25.0 | 17.6 · 23.2 |
| Debt / equity (x) | 0.05 | 0.02 | 0.00 | 0.01 | 0.00 |
| Cash from operations | 9 | 17 | 8 | 28 | 27 |
| Capex | (3) | (2) | (3) | (20) | (14) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33 | 41 | 37 | 41 | 36 | 46 | 43 | 45 |
| Profit before tax | 10 | 13 | 10 | 12 | 10 | 14 | 8 | 14 |
| Net profit | 7 | 10 | 7 | 9 | 8 | 10 | 6 | 11 |
| EPS (₹) | 16.80 | 21.75 | 14.75 | 19.34 | 17.66 | 23.03 | 13.44 | 24.58 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 11.1 | 30.8 | 25 of 158 | 85% |
| P/B | 2.0 | 3.1 | 53 of 163 | 68% |
| ROCE | 22.9 | 10.8 | 21 of 183 | 89% |
| ROE | 17.6 | 9.8 | 28 of 166 | 84% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| EBITDA margin | 32.8 | 17.5 | 25 of 165 | 85% |
| Revenue growth | 8.7 | 16.3 | 98 of 161 | 39% |
| Profit growth | 27.1 | 30.9 | 83 of 158 | 48% |
| Market cap | 386 | 806 | 101 of 181 | 44% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 12 Oct 2026 · Investor crosses 5% stake in Jenburkt Pharmaceuticals via small open market buy | ownership changes | medium | — | — |
| 12 Oct 2026 · Reg 74(5) compliance certificate for Q2 FY27 filed with BSE | compliance | minimal | — | — |
| 22 Sept 2026 · Shares now tradable on NSE under Permitted to Trade category | capital market events | low | — | — |
| 22 Sept 2026 · Trading window closed ahead of Q2 and H1 FY26 results | compliance | minimal | — | — |
| 18 Sept 2026 · SMP resignation at Jenburkt Pharmaceuticals: Sr VP International Business quits | management changes | medium | — | — |
| 4 Sept 2026 · Dilip H. Bhuta reappointed as Whole Time Director and CFO for 5 years | management changes | high | — | — |
| 4 Sept 2026 · AGM Results: All 5 Resolutions Passed Including Rs 20.70 Dividend | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Jenburkt Pharma 41st AGM proceedings: dividend of Rs 20.70 per share declared | board shareholder meetings | low | — | — |
| 4 Sept 2026 · AGM held on 4 Sept 2026; 207 percent dividend declared | board shareholder meetings | low | — | — |
| 4 Sept 2026 · Promoter family member elevated to AVP in senior management | management changes | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.